Everolimus Tablets 10mg Technical Specification:

Product Name:Everolimus Tablets 10mg
Brand Name:Generics
Strength:0.5mg, 0.25mg, 0.75mg, 5mg, 2.5mg, 7.5mg, 10mg
Dosage Form:Tablets
Packing:7s, 10s, 28s, 30s, 60s
Route of Administration:For Oral Use only.
Pack Insert/Leaflet:PIL (Patient Information Leaflet), SmPC (Summary Product Characteristics)
Regulatory Documents:COA, MOA, COPP, FSC, Stability Studies, GMP, CTD Dossier
Therapeutic use:Anti-Cancer
Indication: Everolimus treats cancer by stopping cancer cells from reproducing and by decreasing blood supply to the cancer cells. Everolimus prevents transplant rejection by decreasing the activity of the immune system
Storage:Store at 25°C (77° F); excursions permitted to 15°C to 30°C (59 to 86° F). Store in the original container; protect from light and moisture.

GENERIC NAME OF THE MEDICINAL PRODUCT:

  • Everolimus Tablets 10mg

QUALITATIVE AND QUANTITATIVE COMPOSITION:

  • Everolimus Tablets 10mg
    Each uncoated tablet contains:
    Everolimus…………………..10 mg
    Excipients…………………….q.s.

THERAPEUTIC INDICATIONS:

Everolimus treats cancer by stopping cancer cells from reproducing and by decreasing blood supply to the cancer cells. Everolimus prevents transplant rejection by decreasing the activity of the immune system

CAUTION & WARNING:

CAUTION: It is dangerous to take this preparation except under medical supervision.

WARNING: Cytotoxic Agent: To be sold by retail on the prescription of an oncologist/ Cancer Hospital/ Institution only.

WARNING: To be supplied against demand from Cancer Hospitals, Institutions and against prescription of a Cancer Specialist only.

Keep out of reach and sight of children.

Swallow complete tablet, do not crush or chew.

STORAGE & DOSAGE:

Storage: Store at 25°C (77° F); excursions permitted to 15°C to 30°C (59 to 86° F). Store in the original container; protect from light and moisture.

Dosage: As directed by Oncologist.

For Oral use. Read the package insert before use.

Why Taj Pharmaceuticals?

Selecting the right pharmaceutical provider is a critical decision in the pursuit of health, and Taj Pharmaceuticals has established itself as a beacon of trust and excellence in the industry. Their reputation is built on a foundation of unwavering commitment to quality and a legacy of healthcare expertise that sets them apart.

Quality is not merely a buzzword at Taj Pharmaceuticals; it is a guiding principle. Everolimus Tablets, like all their pharmaceutical products, undergo rigorous quality control measures to meet and exceed industry standards. This commitment assures patients and healthcare professionals that Taj Pharmaceuticals consistently delivers safe and effective medications.

Taj Pharmaceuticals stands at the forefront of pharmaceutical innovation. They don’t just keep pace with healthcare advancements; they drive them. Everolimus Tablets represent their dedication to providing cutting-edge solutions to complex medical challenges, empowering healthcare providers and patients with access to the latest therapeutic options.

More than just a pharmaceutical provider, Taj Pharmaceuticals considers themselves partners in the journey to health. Their unwavering commitment to improving lives makes them a trusted ally in the pursuit of well-being. Patients can trust that their health is Taj Pharmaceuticals’ top priority.

Taj Pharmaceuticals’ global reach ensures that quality healthcare is not bound by borders. Individuals around the world have access to high-quality Everolimus Tablets, breaking down barriers to healthcare accessibility and making life-changing medications universally attainable.

Integrity and trust are paramount in healthcare, and Taj Pharmaceuticals has earned this trust through their ethical practices and patient-centric care. Their role as a responsible pharmaceutical provider is underscored by their unwavering commitment to maintaining the highest standards of integrity.

In summary, Taj Pharmaceuticals emerges as a reliable partner in the journey to health, offering not only medications but a legacy of excellence, innovation, and trust. Choosing Everolimus Tablets from Taj Pharmaceuticals signifies a confident step towards improved health, backed by a steadfast and trustworthy ally.

What is Everolimus Tablets and its uses?

Everolimus Tablets are a pharmaceutical formulation containing the active ingredient everolimus, a powerful drug categorized as an mTOR inhibitor. These tablets find application across a wide spectrum of medical conditions due to their unique ability to modulate cellular processes. One significant application of Everolimus Tablets is in the realm of immunosuppression. They are instrumental in preventing organ rejection in transplant recipients. When a patient undergoes an organ transplant, there is a risk that their immune system may recognize and attack the transplanted organ as foreign. Everolimus plays a crucial role in dampening this immune response, reducing the likelihood of organ rejection. It is often used in combination with other immunosuppressive medications to maintain the proper functioning of the transplanted organ. In the field of oncology, Everolimus Tablets have emerged as a potent tool in the treatment of cancer. They have been employed in managing various types of cancer, including advanced breast cancer, kidney cancer, neuroendocrine tumors, and tumors associated with the rare genetic disorder tuberous sclerosis complex (TSC). Everolimus exerts its anti-cancer effects by disrupting the mTOR pathway, a critical signaling pathway for cell growth and proliferation.

Beyond cancer treatment, Everolimus is a lifeline for individuals with certain rare genetic disorders, such as TSC. When patients with TSC develop tumors like subependymal giant cell astrocytomas (SEGA) in the brain or renal angiomyolipomas in the kidneys, Everolimus can effectively shrink these growths, alleviating associated complications and improving their quality of life. In the context of advanced hormone receptor-positive, HER2-negative breast cancer, Everolimus Tablets are sometimes integrated into treatment regimens, offering a valuable additional therapeutic option. Moreover, Everolimus has gained approval for managing pancreatic neuroendocrine tumors, particularly those of non-functional nature that do not produce significant hormones. Additionally, in cases where lung disease, specifically lymphangioleiomyomatosis (LAM), is associated with TSC, Everolimus has shown promise as a treatment option. Everolimus Tablets are a versatile medication that addresses diverse medical conditions, from preventing organ rejection in transplant patients to providing hope in the battle against cancer and rare genetic disorders. The precise application of Everolimus depends on the individual patient’s medical condition and the guidance of their healthcare provider. Patients should adhere closely to their healthcare provider’s recommendations for the best possible outcomes when using Everolimus Tablets.

How does Everolimus Tablets Work?

Everolimus Tablets are distinguished by their active ingredient, everolimus, which acts through a well-defined mechanism of action centered on the inhibition of the mammalian target of rapamycin (mTOR) pathway. This pathway is pivotal in regulating essential cellular processes, including cell growth, division, and survival.

At its core, Everolimus works by finely tuning the mTOR pathway. In normal circumstances, mTOR is activated in response to specific signals, allowing cells to adjust their growth and proliferation accordingly. However, in certain medical conditions like cancer and genetic disorders such as tuberous sclerosis complex (TSC), this pathway goes awry, resulting in uncontrolled cell growth.

Everolimus, as an mTOR inhibitor, steps in to restore balance. It selectively hinders the activity of mTOR within cells, disrupting the signaling cascade downstream of this protein. This interference prevents cells from receiving the “green light” for growth. Notably, Everolimus’s impact is particularly pronounced in rapidly dividing cells, which makes it a powerful tool in addressing conditions characterized by abnormal cell growth.

As Everolimus effectively inhibits the mTOR pathway, it has a substantial impact on the cell cycle—the sequence of stages that cells navigate, including growth, DNA replication, and division. By blocking mTOR, Everolimus impedes the cell cycle’s progression. Consequently, cells that rely on mTOR for their continuous growth are halted in their tracks, unable to proceed to the division phase.

Moreover, Everolimus induces a programmed cell death process known as apoptosis in these arrested cells. Apoptosis is a natural mechanism by which the body eliminates damaged or unnecessary cells. In the context of cancer treatment, Everolimus promotes the apoptosis of cancer cells, reducing their numbers and effectively controlling tumor growth.

In summary, Everolimus Tablets’s mode of action centers on the precise targeting of the mTOR pathway, a central regulator of cell growth and proliferation. By selectively inhibiting mTOR, Everolimus disrupts the cell cycle, induces apoptosis, and curbs the growth of rapidly dividing cells. This mechanism is a cornerstone in the treatment of conditions marked by abnormal cell growth, including specific cancers and genetic disorders. The specific application of Everolimus Tablets is determined by the patient’s medical condition and the recommendations of their healthcare provider.

Benefits of Everolimus Tablets:

Everolimus Tablets offer a range of significant benefits across various medical conditions. In the field of oncology, Everolimus stands as a powerful tool in the treatment of cancer. It demonstrates effectiveness against advanced breast cancer, kidney cancer, and neuroendocrine tumors. By disrupting the mTOR pathway, Everolimus inhibits the growth of cancer cells, providing hope for patients battling these diseases.

Furthermore, Everolimus plays a critical role in immunosuppression, a crucial aspect of organ transplantation. By suppressing the immune system’s response to a transplanted organ, it enhances the likelihood of successful transplantation, allowing patients to embrace a healthier life with their new organs.

For individuals grappling with rare genetic disorders like tuberous sclerosis complex (TSC), Everolimus can be a life-altering intervention. It effectively manages conditions such as subependymal giant cell astrocytomas (SEGA) in the brain and renal angiomyolipomas in the kidneys, significantly improving the quality of life for these patients.

In cases of lung disease associated with TSC, known as lymphangioleiomyomatosis (LAM), Everolimus offers substantial benefits. By slowing disease progression and enhancing lung function, it brings about tangible improvements in the well-being of these patients.

Side Effects of Everolimus Tablets:

While Everolimus Tablets offer substantial therapeutic benefits, they are also associated with certain side effects that necessitate close monitoring:

Patients receiving Everolimus may experience a heightened risk of infections due to its immunosuppressive effects. Vigilant monitoring and prompt medical attention are crucial in managing potential infections.

Some individuals may develop oral ulcers or sores while on Everolimus treatment. These symptoms should be promptly reported to healthcare providers.

Fatigue is a common side effect of Everolimus, potentially impacting daily activities. Patients are advised to prioritize rest and energy conservation to manage this fatigue.

Skin-related issues, such as rashes, itching, and acne, are reported side effects of Everolimus treatment.

Gastrointestinal discomfort, including nausea, diarrhea, and abdominal pain, may occur. These symptoms can often be effectively managed with appropriate medications.

Metabolic changes, including elevated blood sugar and cholesterol levels, may occur with Everolimus. Regular monitoring and intervention are crucial in addressing these effects.

Everolimus can lead to a reduction in blood cell counts, potentially causing anemia, leukopenia, and thrombocytopenia. This can increase the risk of infections and bleeding.

Kidney function may be affected by Everolimus, necessitating regular monitoring through blood tests.

In some cases, Everolimus can lead to lung-related issues, including cough, shortness of breath, and interstitial lung disease.

It’s imperative for patients to communicate openly with their healthcare providers about any side effects experienced during Everolimus therapy. This enables timely intervention and management, ensuring the best possible outcome from treatment. The benefits of Everolimus often outweigh potential side effects, especially in critical medical conditions, such as cancer and organ transplantation.

Frequently Asked Questions About Everolimus Tablets

  1. What are Everolimus Tablets used for?

Everolimus Tablets are prescribed for various medical conditions, including cancer treatment (e.g., breast cancer, kidney cancer), immunosuppression in transplant recipients, and management of rare genetic disorders like tuberous sclerosis complex (TSC).

  1. How does Everolimus work in cancer treatment?

Everolimus inhibits the mTOR pathway, a critical signaling pathway for cell growth and proliferation. By disrupting this pathway, it effectively controls the growth of cancer cells and slows down tumor progression.

  1. What are the common side effects of Everolimus Tablets?

Common side effects include fatigue, mouth sores, skin rashes, gastrointestinal issues (nausea, diarrhea), metabolic changes (high blood sugar, high cholesterol), decreased blood cell counts (anemia, leukopenia, thrombocytopenia), potential kidney effects, and lung-related symptoms in some cases.

  1. Is Everolimus safe for use in transplant recipients?

Yes, Everolimus is used to prevent organ rejection in transplant recipients. Its immunosuppressive properties help reduce the risk of the recipient’s immune system attacking the transplanted organ.

  1. Can Everolimus be used for the treatment of rare genetic disorders?

Yes, Everolimus is approved for managing certain manifestations of rare genetic disorders like tuberous sclerosis complex (TSC), including the treatment of brain tumors (SEGA) and kidney tumors (angiomyolipomas).

  1. How should Everolimus Tablets be taken?

Everolimus Tablets should be taken exactly as prescribed by a healthcare provider. The dosage and administration schedule will depend on the patient’s medical condition. It’s essential to follow the provider’s instructions meticulously.

  1. Can Everolimus interact with other medications?

Yes, Everolimus can interact with other drugs, potentially affecting their efficacy or safety. Patients should inform their healthcare providers about all medications, supplements, or herbal products they are taking to prevent potential interactions.

  1. What should I do if I experience side effects while taking Everolimus?

If you experience side effects, promptly notify your healthcare provider. They can provide guidance on managing side effects, adjusting the dosage, or considering alternative treatments if necessary.

  1. Is Everolimus safe during pregnancy and breastfeeding?

Everolimus may harm a developing fetus, so it is generally not recommended during pregnancy. Women of childbearing age should use effective contraception during treatment. Breastfeeding is also discouraged while taking Everolimus due to potential risks to the infant.

  1. Can Everolimus be abruptly discontinued?

No, Everolimus should not be discontinued without consulting a healthcare provider. Abrupt discontinuation can lead to complications, especially in transplant recipients. Any changes to the treatment plan should be discussed with a healthcare professional.

Patients prescribed Everolimus Tablets should consult their healthcare provider for personalized information and guidance tailored to their specific medical condition and treatment regimen.

As Everolimus Tablets Exporters; We can cater to export business queries from the following geographies. We are exporting our Everolimus Tablets product in the Following Countries-

Russia and CIS Countries: Azerbaijan, Armenia, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, Turkmenistan, Uzbekistan and Ukraine

GCC/ Middle East Countries: Saudi Arabia, Yemen, Oman, Bahrain, UAE, Lebanon, Jordan, and Iraq.

African Countries: Nigeria, Tanzania, Sudan, Zambia, Benin, Angola, Liberia

Southeast Asia: Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, Vietnam, Brunei Darussalam

Other Asian Countries: Nepal, Myanmar, Malaysia, Cambodia, Bhutan, Sri Lanka, Mauritius

Everolimus Tablets Regulatory Documents:

  • Certificate of Analysis (COA)
  • Method of Analysis (MOA)
  • Stability Data (Accelerated stability / Long-term stability / Zone 4b)
  • CTD Dossier / ACTD Dossiers / eCTD Dossiers
  • Certificate of Pharmaceuticals Product (COPP)
  • Free Sale Certificate (FSC)
Contact the most reliable manufacturer of  Everolimus Tablets, Taj Pharmaceuticals Limited, to get bulk quantities at a reasonable price.

To Place Orders:

Direct line: +91 8448 444 095 / WhatsApp +91 74 0000 9975 / 74 0000 9976
E-Mail: info@tajpharma.com
Toll free: 1-800-222-434 / Toll free: 1-800-222-825
General EPA BX: +91 22 2637 4592 / +91 22 2637 4593
Fax No: +91 22 2634 1274

GENERIC NAME OF THE MEDICINAL PRODUCT:

a) Everolimus Tablets 0.5mg
b) Everolimus Tablets 0.25mg
c) Everolimus Tablets 0.75mg
d) Everolimus Tablets 5mg
e) Everolimus Tablets 2.5mg
f) Everolimus Tablets 7.5mg
g) Everolimus Tablets 10mg

QUALITATIVE AND QUANTITATIVE COMPOSITION:

a) Everolimus Tablets 0.5mg
Each uncoated tablet contains:
Everolimus…………………..0.5 mg
Excipients…………………….q.s.

b) Everolimus Tablets 0.25mg
Each uncoated tablet contains:
Everolimus………………..0.25 mg
Excipients………………….q.s.

c) Everolimus Tablets 0.75mg
Each uncoated tablet contains:
Everolimus…………………0.75 mg
Excipients………………….q.s.

d) Everolimus Tablets 5mg
Each uncoated tablet contains:
Everolimus……………………..5 mg
Excipients……………………….q.s.

e) Everolimus Tablets 2.5mg
Each uncoated tablet contains:
Everolimus…………………..2.5 mg
Excipients……………………q.s.

f) Everolimus Tablets 7.5mg
Each uncoated tablet contains:
Everolimus…………………..7.5 mg
Excipients…………………….q.s.

g) Everolimus Tablets 10 mg
Each uncoated tablet contains:
Everolimus……………………10 mg
Excipients……………………..q.s.


THERAPEUTIC INDICATIONS:

Everolimus treats cancer by stopping cancer cells from reproducing and by decreasing blood supply to the cancer cells. Everolimus prevents transplant rejection by decreasing the activity of the immune system

CAUTION & WARNING:

CAUTION: It is dangerous to take this preparation except under medical supervision.
WARNING: Cytotoxic Agent: To be sold by retail on the prescription of an oncologist/ Cancer Hospital/ Institution only.
WARNING: To be supplied against demand from Cancer Hospitals, Institutions and against prescription of a Cancer Specialist only.
Keep out of reach and sight of children.
Swallow complete tablet, do not crush or chew.

STORAGE & DOSAGE:

Storage: Store at 25°C (77° F); excursions permitted to 15°C to 30°C (59 to 86° F). Store in the original container; protect from light and moisture.
Dosage: As directed by Oncologist.
For Oral use. Read the package insert before use.